抗苗勒管激素用于多囊卵巢综合征诊断的研究进展  

Research progress of anti-Müllerian hormone in the diagnosis of polycystic ovary syndrome

作　　者：刘谢芹 曾玖芝[2] 刘伟信[2] 魏雅琴 Liu Xieqin;Zeng Jiuzhi;Liu Weixin;Wei Yaqin(Chengdu Medical College,Chengdu 610500,China;Center for Reproductive Medicine,Sichuan Maternal and Child Health Hospital,Chengdu 610041,China)

机构地区：[1]成都医学院,610500 [2]四川省妇幼保健院生殖医学中心,成都610041

出　　处：《中华生殖与避孕杂志》2020年第12期1026-1030,共5页Chinese Journal of Reproduction and Contraception

基　　金：四川省卫生和计划生育委员会项目(17PJ242);四川省科学技术厅项目(2017JY0321)。

摘　　要：多囊卵巢综合征(polycystic ovary syndrome,PCOS)患者血清中抗苗勒管激素(anti-Müllerian hormone,AMH)水平较正常女性高。近年越来越多的研究提示,AMH与雄激素相互作用导致PCOS患者卵泡发育障碍,AMH可作为诊断PCOS的生化指标,尤其是在高雄激素血症的PCOS患者中。本文就AMH用于PCOS诊断的前景及挑战进行综述。The level of anti-Müllerian hormone(AMH)in the serum of patients with polycystic ovary syndrome(PCOS)was higher than that of normal women.In recent years,more and more studies have suggested that the interaction between AMH and androgen causes follicular developmental disorder in PCOS patients,and AMH can be used as a biochemical indicator for the diagnosis of PCOS,especially in PCOS patients with hyperandrogenism.This paper reviews the prospects and challenges of AMH in the diagnosis of PCOS.

关 键 词：多囊卵巢综合征 抗苗勒管激素 高雄激素血症 

分 类 号：R711.75[医药卫生—妇产科学]